Abstract Number: L02 • ACR Convergence 2023
Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE
Background/Purpose: Endosomal nucleic acid-sensing toll-like receptors 3, 7 and 9 are key innate immune sensors of dsRNA, ssRNA and ssDNA, respectively, whose activities must be…Abstract Number: L13 • ACR Convergence 2023
An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus: Preliminary Results
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by pathogenic autoreactive B cells producing autoantibodies against multiple self-antigens. Recently, a series of clinical cases suggested that…Abstract Number: L17 • ACR Convergence 2023
Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Over 50 years have passed since the last therapy was approved for cutaneous lupus erythematosus (CLE).1 Parenteral administration, off-label use, or toxicity with long-term…Abstract Number: 0120 • ACR Convergence 2023
Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study
Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…Abstract Number: 0184 • ACR Convergence 2023
Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE
Background/Purpose: Lower socioeconomic status is associated with greater disease activity and mortality in systemic lupus erythematosus (SLE); however, mechanisms driving this are yet to be…Abstract Number: 0463 • ACR Convergence 2023
Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Background/Purpose: Pregnancies complicated by systemic lupus erythematosus (SLE) are known to be at high risk for adverse pregnancy outcomes (APOs). Previous studies have shown that…Abstract Number: 0555 • ACR Convergence 2023
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
Background/Purpose: The management of a positive anti-nuclear antibody (ANA) is one of the most common consultations in rheumatology outpatient practice. The prevalence of a positive…Abstract Number: 0572 • ACR Convergence 2023
Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis
Background/Purpose: CD163 is a glycosylated membrane protein expressed in monocytes and macrophages that phagocytize the hemoglobin/haptoglobin complex. As a result of proinflammatory stimuli, CD163 is…Abstract Number: 0590 • ACR Convergence 2023
Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), originally approved as oral hypoglycemic agents for type 2 diabetes (T2D), have been shown to reduce progression to end-stage…Abstract Number: 0723 • ACR Convergence 2023
Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious complication in SLE patients, with rapid progression and poor prognosis. In China, approximately 3% of the over…Abstract Number: 0848 • ACR Convergence 2023
Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
Background/Purpose: Disease flare and infections are the major causes of fever in a patient with SLE. It is vital to differentiate between these two as…Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…Abstract Number: 0924 • ACR Convergence 2023
Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE
Background/Purpose: Complement plays a central role in SLE, generating an array of bioactive soluble and cell-bound complement activation products (CB-CAPs) during disease activity. Data are…Abstract Number: 1094 • ACR Convergence 2023
“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is the most common cause of kidney injury in patients with systemic lupus erythematous (SLE) and is associated with higher morbidity…Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
- 1
- 2
- 3
- …
- 119
- Next Page »